Modern immunotherapy for the treatment of prostate cancer

Immunotherapy for prostate cancer became a therapeutic option for metastatic castration-resistant prostate cancer after a phase III trial of sipuleucel-T demonstrated an overall survival advantage relative to placebo. A similar phase II trial in the same population but with the vaccine PSA-TRICOM also demonstrated an overall survival advantage. As these and similar immunotherapeutic options for prostate cancer emerge, it becomes important to understand their unique characteristics and potential benefits.